• Cancel
    Date:2021-03

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2021-03

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=546

    In Shanghai, on February 24, 2021 – WuXi Diagnostic Investment (Cayman) Limited ("WuXi Diagnostics") announced that it has completed US$150 million in series B funding, joined by new investors including Thermo Fisher Scientific Inc. ("Thermo Fisher"), Shiyu Capital ("SHIYU"), ABC International Holdings Limited ("ABC International"), Sunland Capital and CCBI Tech Venture, alongside existing shareholder YF Capital, with CEC Capital Group serving as the exclusive financial adviser. WuXi Diagnostics will deploy funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline, and accelerate market penetration in the global diagnostics sector.

  • Cancel
    Date:2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=546

    In Shanghai, on February 24, 2021 – WuXi Diagnostic Investment (Cayman) Limited ("WuXi Diagnostics") announced that it has completed US$150 million in series B funding, joined by new investors including Thermo Fisher Scientific Inc. ("Thermo Fisher"), Shiyu Capital ("SHIYU"), ABC International Holdings Limited ("ABC International"), Sunland Capital and CCBI Tech Venture, alongside existing shareholder YF Capital, with CEC Capital Group serving as the exclusive financial adviser. WuXi Diagnostics will deploy funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline, and accelerate market penetration in the global diagnostics sector.

  • Cancel
    Date:2021-02

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=519

    Guangzhou Weiyuan (Vision Medicals) Gene Technology Co., Ltd. (hereinafter referred to as “Vision Medicals” or the “Company”), a leader in the infection precision medicine industry, recently announced the completion of a Series B financing round of several hundred million RMB. This round of financing was led by CDH Investment, with participation from CICC Qichen and existing shareholders, Volcanics Venture and Cash Capital. This round of financing will primarily be used for funding product R&D, establishing a clinical testing network, driving product registration efforts, constructing manufacturing facilities, improving clinical services, and increasing brand marketing. CEC Capital Group served as the exclusive financial advisor of Vision Medicals in this transaction.

  • Cancel
    Date:2021-02

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2021-01

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2020-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=535

    CEC Capital Group serves as exclusive financial advisor Beijing Haosi (Health) Biotechnology Co., Ltd. (hereinafter referred to as "Haosi Bio" or the "Company"), a leading provider of solutions for clinical mass spectrometry detection, today announced th